Literature DB >> 2848207

Effects of 4-aminopyridine in experimental CNS demyelination.

R Kaji1, A J Sumner.   

Abstract

We studied the effect of systemically administered 4-aminopyridine in a model of CNS demyelination. In five rats with demyelination, slowed conduction velocity through the lesion was partially reversed at dose levels of 5.6 to 7.2 mg/kg. All rats developed convulsion at this dosage, and impaired conduction of high-frequency impulses was unchanged. These findings suggest certain limitations of 4-aminopyridine as a therapeutic agent.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2848207     DOI： 10.1212/wnl.38.12.1884

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  4 in total

1.  Sustained-released fampridine in multiple sclerosis: effects on gait parameters, arm function, fatigue, and quality of life.

Authors:  Etienne Allart; Anne Benoit; Anne Blanchard-Dauphin; Vincent Tiffreau; André Thevenon; Hélène Zephir; Olivier Outteryck; Arnaud Lacour; Patrick Vermersch
Journal:  J Neurol       Date:  2015-06-05       Impact factor: 4.849

Review 2.  Potassium channel blockers as an effective treatment to restore impulse conduction in injured axons.

Authors:  Riyi Shi; Wenjing Sun
Journal:  Neurosci Bull       Date:  2011-02       Impact factor: 5.203

3.  Cortical Excitability Measures May Predict Clinical Response to Fampridine in Patients with Multiple Sclerosis and Gait Impairment.

Authors:  Rechdi Ahdab; Madiha M Shatila; Abed Rahman Shatila; George Khazen; Joumana Freiha; Maher Salem; Karim Makhoul; Rody El Nawar; Shaza El Nemr; Samar S Ayache; Naji Riachi
Journal:  Brain Sci       Date:  2019-12-05

4.  Sustained-release fampridine (4-aminopyridine) in multiple sclerosis: efficacy and impact on motor function.

Authors:  Meheroz H Rabadi; Kimberly Kreymborg; Andrea S Vincent
Journal:  Drugs R D       Date:  2013-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.